Design characteristics that influence attrition in geriatric antidepressant trials: meta-analysis
- PMID: 19263464
- DOI: 10.1002/gps.2211
Design characteristics that influence attrition in geriatric antidepressant trials: meta-analysis
Abstract
Objective: To identify study-level and treatment group-level characteristics that are associated with attrition in antidepressant trials for the depressed elderly.
Methods: This meta-analysis used 68 published antidepressant randomized trials for the elderly depressed. Study-level and treatment group-level variables were extracted. The former consisted of: use of placebo arm, number of arms, unbalanced treatment allocation, year conducted, study duration, study location, number of centers, and patient pool. The latter consisted of: assigned treatments, baseline mean Hamilton Depression Rating Scale (HDRS), baseline mean age, gender ratio, attrition size, and sample size. Univariate logistic regressions with attrition as the dependent variable were applied, followed by application of a forward stepwise selection method for identification of independent attrition correlates.
Results: The 68 studies had a total of 153 treatment groups and 8,385 subjects. Among them, 2,287 subjects were terminated early, resulting in an overall 27.3% attrition rate. The stepwise results showed that higher attrition was significantly associated with active antidepressant groups as opposed to placebo groups, higher baseline HDRS, smaller sample size, unbalanced allocation of treatments, longer duration, and studies conducted in USA.
Conclusions: The attrition in geriatric antidepressant trials can be affected by study and group-level design characteristics that include severity of depression symptoms and active treatments among others.
Copyright (c) 2009 John Wiley & Sons, Ltd.
Similar articles
-
Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.Eur Neuropsychopharmacol. 2010 Aug;20(8):562-7. doi: 10.1016/j.euroneuro.2010.02.004. Epub 2010 Mar 9. Eur Neuropsychopharmacol. 2010. PMID: 20219330
-
The mousetrap: managing the placebo effect in antidepressant trials.Mol Interv. 2002 Apr;2(2):72-6. doi: 10.1124/mi.2.2.72. Mol Interv. 2002. PMID: 14993352 Review. No abstract available.
-
Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.J Psychiatr Res. 2005 Mar;39(2):145-50. doi: 10.1016/j.jpsychires.2004.06.005. J Psychiatr Res. 2005. PMID: 15589562 Clinical Trial.
-
Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies.Pharmacotherapy. 2009 Dec;29(12):1408-16. doi: 10.1592/phco.29.12.1408. Pharmacotherapy. 2009. PMID: 19947800 Review.
-
[Placebo-controlled antidepressant drug trials. Considering the ethical implications].Fortschr Neurol Psychiatr. 2003 May;71(5):243-8. doi: 10.1055/s-2003-39050. Fortschr Neurol Psychiatr. 2003. PMID: 12740755 Review. German.
Cited by
-
Impact of subject attrition on sample size determinations for longitudinal cluster randomized clinical trials.J Biopharm Stat. 2014;24(3):507-22. doi: 10.1080/10543406.2014.888442. J Biopharm Stat. 2014. PMID: 24697555 Free PMC article.
-
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials.BMJ. 2025 Apr 28;389:e081660. doi: 10.1136/bmj-2024-081660. BMJ. 2025. PMID: 40294956 Free PMC article.
-
Participant and trial characteristics reported in predictive analyses of trial attrition: an umbrella review of systematic reviews of randomised controlled trials across multiple conditions.Trials. 2025 Mar 12;26(1):84. doi: 10.1186/s13063-025-08794-x. Trials. 2025. PMID: 40075486 Free PMC article.
-
Impact of length or relevance of questionnaires on attrition in online trials: randomized controlled trial.J Med Internet Res. 2011 Nov 18;13(4):e96. doi: 10.2196/jmir.1733. J Med Internet Res. 2011. PMID: 22100793 Free PMC article. Clinical Trial.
-
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586. BMJ. 2013. PMID: 23303884 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical